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CD4 recovery after 4 years of antiretroviral
therapy in an African cohort
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Yukari C Manabe2, Rose Nabatanzi 3, Moses R Kamya1, Huyen Cao4
Abstract
Background: Antiretroviral therapy (ART) partially corrects immune dysfunction associated with HIV infection. The
levels of T-cell immune activation and exhaustion after long-term, suppressive ART and their correlation with CD4
T-cell count reconstitution among ART-treated patients in African cohorts have not been extensively evaluated.
Methods: T-cell activation (CD38+HLA-DR+) and immune exhaustion (PD-1+) were measured in a prospective
cohort of patients initiated on ART; 128 patient samples were evaluated and subcategorized by CD4 reconstitution
after long-term suppressive treatment: Suboptimal [median CD4 count increase 129 (-43-199) cells/μl], N = 34],
optimal [282 (200-415) cells/μl, N = 64] and super-optimal [528 (416-878) cells/μl, N = 30].
Results: Both CD4+ and CD8 T-cell activation was significantly higher among suboptimal CD4 T-cell responders
compared to super-optimal responders. In a multivariate model, CD4+CD38+HLADR+ T-cells were associated with
suboptimal CD4 reconstitution [AOR, 5.7 (95% CI, 1.4-23, P = 0.014)]. T-cell exhaustion (CD4+PD1+ and CD8+PD1+)
was higher among suboptimal relative to optimal (P < 0.001) and super-optimal responders (P < 0.001). T-cell
exhaustion was significantly associated with suboptimal responders [AOR, 1.5 (95%CI, 1.1-2.1), P = 0.022].
Conclusion: T-cell activation and exhaustion persist among HIV-infected patients despite long-term, sustained HIV-RNA
viral suppression. These immune abnormalities were associated with suboptimal CD4 reconstitution and their
regulation may modify immune recovery among suboptimal responders to ART.
Background
Although antiretroviral therapy (ART) partially corrects
immune dysfunction associated with HIV infection,
abnormalities of immune activation markers persist in
many patients [1-3]. ART reduces the levels of T-cell
activation by mechanisms independent of viral load
[1-3]. Nevertheless, immune activation (as measured by
expression of HLA-DR and CD38 on monocytes and
T-cells) remained significantly higher among HIV-
infected patients relative to the HIV-negative controls
one year after viral suppression [4].
Up to 40% of individuals receiving ART have suboptimal
CD4 T-cell recovery despite sustained HIV-RNA viral sup-
pression [5-7]. HIV-RNA viremia and T-cell immune acti-
vation have been previously shown to be strong predictors
of HIV disease progression [8]. In contrast, there is con-
flicting data on the influence of T-cell activation on CD4
T-cell recovery among patients on successful ART [9,10].
Furthermore, there is limited data on the influence of
immune activation on CD4 count and functional recovery
with sustained HIV-RNA suppression in African popula-
tions [11,12], where endemic co-infections may dampen
the immune response [13].
Increased T-cell apoptosis has been proposed as a
mechanism for unsatisfactory immune recovery [7]. PD-1
expression is increased during HIV-1 infection [14] and
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negatively regulates T-cell activity and can be measured
by T-cell expression of Programmed Death-1 (PD-1)
marker, an inducible molecule that is expressed on all
lymphoid cells that are highly susceptible to apoptosis
[15,16]. This study reports the levels of T-cell immune
activation and T-cell exhaustion among adult Ugandans
with sustained HIV-RNA viral suppression after 4 years
of ART.
Methods
Study setting and participants
Between April, 2004 and April, 2005, 559 consecutive
ART-naïve HIV-infected patients, were initiated on ART
and enrolled into the Infectious Diseases Institute (IDI)
prospective observational research cohort as previously
described [17]. Patients were initiated on first-line ART
at CD4 counts ≤ 200 cells/μl according to Ugandan
guidelines for ART initiation at the time. Drugs were
provided through the Global Fund (a generic combined
formulation of stavudine [d4T, lamivudine [3TC], and
nevirapine [NVP] and the US President’s Emergency
Plan for AIDS Relief (a combined formulation of zidovu-
dine [ZDV] and 3TC plus efavirenz [EFZ] or nevirapine
[NVP]. Patients with toxicity to ZDV were changed to
tenofovir [TDF]. All patients received cotrimoxazole (or
dapsone) prophylaxis according to the national policy to
provide cotrimoxazole to all people living with HIV
(PLHIV). Adherence to ART was encouraged by at least
3 individual and group counseling sessions. Patients
were reviewed monthly by the study physicians that
evaluated among others; adherence to medication, toxi-
cities and acute infections. HIV RNA viral loads, com-
plete blood counts and CD4 lymphocyte counts were
measured 6 monthly intervals.
After 4 years of follow up on ART, 252/559 (45%)
patients had sustained HIV-RNA viral suppression. Of
these, 41 were excluded due to the following reasons;
death (n = 25), lost to follow-up (n = 5), voluntary
request to transfer to and voluntary termination from
the study (n = 11). We excluded patients that had an
opportunistic infection in the previous 6 months. Up to
128 patients with chronic HIV infection successfully
suppressed on ART with HIV RNA levels < 400 copies/
ml for 4 years were evaluated: 34 patients (cases) with
suboptimal CD4 reconstitution, 64 with optimal CD4
reconstitution (controls) and 30 with super-optimal CD4
reconstitution (controls); see Figure 1.
Definition of suboptimal CD4 reconstitution
Various definitions have been used to describe subopti-
mal CD4 reconstitution following ART including the mag-
nitude of the CD4 cell increase [18]. Kaufmann et al
defined suboptimal CD4 reconstitution an absolute CD4
count < 500 cells/μl after 5 years of sustained viral loads
< 1000 copies [19]. However, less than one-third of all the
patients in our African study cohort had attained an abso-
lute CD4 count ≥ 500 cells/μl. Therefore we used a cohort-
specific definition of suboptimal CD4 reconstitution in
order to consider the whole spectrum of CD4 recovery.
The magnitude of CD4 increase (difference between abso-
lute CD4 counts at baseline and absolute CD4 counts after
4 years of ART), for the 211 patients with sustained HIV-
RNA viral suppression, was grouped into 4 quartiles. Cases
of ’Suboptimal CD4 reconstitution’ included patients
within the lowest quartile and the controls with ’Optimal
CD4 reconstitution’ included patients within the two mid-
dle quartiles while the controls with ’Super-optimal CD4
reconstitution’ included patients within the highest quar-
tile of CD4 increase (see Figure 1). Written informed con-
sent was obtained from all participants. This study was
approved by national institutional review board;
the Uganda National Council of Science and Technology.
The immunology assays were performed at the cytotoxic
T lymphocyte laboratory (CTL) at the Joint clinical
research center (JCRC), Kampala, Uganda.
PBMC separation
Fifty mls of whole blood, collected in ACD-A bottles,
was processed for PBMC separation within 4 hours of
collection. PBMCs were separated by Ficoll-Hypaque
density configuration, washed and re-suspended in
phosphate buffer saline (PBS) containing heat inacti-
vated fetal calf serum (FCS). PBMCs were frozen and
stored in FBS with 10% dimethyl sulfoxide (DMSO), in
liquid nitrogen until assay time.
Cell surface staining for immune profile
PBMC were thawed and rested overnight before surface
staining. PBMC viability was 90% and above. Surface
staining for immune profile was done in two panels by
incubating with the following antibodies; CD3 APC,
CD4 PerCP-Cy5.5, HLA-DR FITC and CD38 PE (BD
Biosciences San Jose, CA) for immune activation and
CD3 FITC, CD4 PerCP-Cy5.5, PD-1 APC and CD127
PE (BD Biosciences San Jose, CA) for cell function/
exhaustion. The florescence signals were measured by
4-color flow Facscalibur
(BD Biosciences San Jose, CA). In general, at least
50,000 events in the CD3-positive gate were collected.
Gating was standardized and set using fluorescence
minus one controls (FMOs) for HLADR, CD38 and PD-
1. Data were analyzed using FLOWJO software (TreeS-
tar, San Carlos, CA). Immune activation was defined as
the percent of CD38+ HLA DR+ T-cells. PD-1 level was
defined as the percent expression of PD-1 APC CD3+
CD8+ (or CD4+) T-cells, respectively.
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Co-infections
All participants were tested for concurrent acute infec-
tions that are associated with immune activation.
Among other tests, patients were tested for hepatitis B
surface antigen (hepatitis B surface antigen version 3,
Murex Biotech LTD, Darford, UK) and intestinal hel-
minthes (using stool microscopy for parasites, ova and
cysts and modified ZN stain for cryptosporidia infesta-
tions) as well as C-reactive protein levels, a biomarker
for acute non-specific acute infection.
Statistical analysis
We compared percentages of activated (CD38+HLADR+)
T-cells between patients with suboptimal, optimal and
super-optimal CD4 reconstitution after 4 years of ART
with plasma HIV-RNA levels below 400 copies/ml. Chi
square and Kruskal-Wallis tests were used for unadjusted
comparisons between the three groups for categorical and
continuous variables respectively. Wilcoxon rank sum test
was used compare immunological and clinical parameters
among suboptimal and super-optimal responders. Logistic
559 initiated ART 
 69% female 
 Median age 38 (33-44) yrs 
 51% had baseline CD4 count <100 cells/ ȝl 
 74% initiated ͶΪ͵ΪƬʹ͸ΨΪ͵Ϊ	
252 has sustained viral suppression up to 4 years 
25 died (15-HIV/AIDS-related deaths, 6 –other medical 
 Illnesses, 4 cause of death cannot be 
determined) 
7 transferred out to other ART centers 
5 lost to follow up 
4 withdrew consent to participate in the research cohort 
0 patients with a reported opportunistic infection (s) 6 
months prior to the study 
52 in the lowest quartile 
of CD4 reconstitution  
Median CD4 increase 129 
(Range -43-199) cells/ȝl 
34 cases  
‘Suboptimal’ responders 
systematically selected 
104 in the 2nd & 3rd 
quartiles of CD4 increase  
Median CD4 increase 282 
(Range 200-415) cells/ȝl 
64 ‘Optimal’ responders 
systematically selected 
52 in the highest quartiles of 
CD4 increase  
Median CD4 increase 528 
(Range 416-878) cells/ȝl 
30 ‘Super-optimal’ 
responders systematically 
Selected 
211 patients were 
eligible for current study 
Figure 1 Profile of patients on antiretroviral therapy within the Infectious Disease research cohort.
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regression was used to determine relationship between T-
cell activation and CD4 reconstitution. All factors that
were significant predictors of suboptimal CD4 reconstitu-
tion in unadjusted analyses (P < .10) were included in the
multivariate model in a stepwise manner.
Results
Characteristics of participants
Overall, 128 individuals with sustained HIV-RNA viral
loads < 400 copies/ml after 4 years of ART were evalu-
ated: 34 patients with ‘suboptimal CD4 reconstitution’,
64 with ‘optimal CD4 reconstitution ’ and 30 with
‘super-optimal CD4 reconstitution’. Median CD4 count
increase (difference between baseline and 4 years of
ART) was 129 (-43-199), 282 (200-415) and 528 (416-
878) cells/μl for the suboptimal, optimal and super-
optimal respectively (see Figure 1). Baseline clinical
characteristics were similar among the three patient
categories both at baseline and after 4 years of ART
except CD4 counts that were significantly different
after 4 years of ART (P < 0.001); see Table 1.
T-cell activation
T-cell activation was measured by co-expression CD38
and HLADR (CD4+ CD38+HLADR+ and CD8+CD38
+HLADR+) on the T cell surface (see Figure 2). CD4
and CD8 T-cell activation was significantly higher
among ‘suboptimal’ responders compared with the ‘opti-
mal’ (p < 0.001) and ‘super-optimal’ responders (p <
0.001); see Figure 3. In addition, CD4+CD38+HLADR+
T-cells were independent predictors of suboptimal CD4
reconstitution [Adjusted odds ratio, AOR, 5.7 (95% con-
fidence interval, 95%CI, 1.4-23, P = 0.014)].
T-cell exhaustion
Immune exhaustion was measured by expression of PD-
1 on CD4 (CD4+PD1+) and CD8 (CD8+PD1+) T-cells
(see Figure 4). PD-1 expression was significantly higher
among ‘suboptimal responders’ compared with the opti-
mal (p < 0.001) and ‘super-optimal’ (p < 0.001) respon-
ders (see Figure 5). CD4+PD1+ remained significantly
higher among suboptimal responders at multivariate
analysis [AOR, 1.5 (95%CI 1.1-2.1), P = 0.022]; see
Table 2.
Peripheral blood parameters
The total white blood cell count and eosinophil percen-
tage were significantly lower among suboptimal respon-
ders relative to super-optimal responders; P-values;
<0.003, and 0.012 respectively (see Table 2). However, at
Table 1 Characteristics of 128 patients with sustained viral suppression after 4 years of antiretroviral therapy at the
Infectious Diseases Institute research cohort∏
Sub-optimal CD4 reconstitution
(Cases)
N = 34
Optimal CD4 reconstitution
(Controls)
N = 64
Super-optimal CD4 reconstitution
(Controls)
N = 30
P value*
At baseline
Age (yrs) [median (IQR)] 36 (31-42) 33 (30-38) 35 (31-43) 0.509
Female gender [n (%)] 21 (62) 49 (77) 26 (87) 0.066
BMI [median (IQR)] 20 (19-23) 20 (19-23) 20 (19-23) 0.935
CD4 cells/μl [median (IQR)] 111 (62-151) 105 (40-176) 115 (97-185) 0.447
< 100 cells/μl [n(%)] 20 (59) 35 (55) 15 (30) 0.779
ART regimen
D4T-3TC-NVP/EFZ [n (%)] 17 (50) 43 (67) 22 (73)
ZDV-3TC-NVP/EFZ [n (%)] 17 (50) 21 (33) 8 (27) 0.116
Hemoglobin [ median (IQR)] 12 (11-13) 11 (10-13) 11 (10-13) 0.473
After 4 years of ART
CD4 cells/μl [median (IQR)] 220 (183-248) 407 (334-456) 985 (438-1290) < 0.001
< 350 cells/μl [n(%)] 34 (100) 19 (30) 0 (0) < 0.001
BMI [median (IQR)] 21 (19-25) 22 (20-24) 22 (20-24) 0.062
Hemoglobin [ median (IQR)] 14 (12-15) 13 (12-14) 13 (12-14) 0.969
Hepatitis B positive [n] 1 5 1 0.033
ART regimen
D4T-3TC-NVP/EFZ [n (%)] 13 (38) 41 (64) 17 (57)
ZDV-3TC-NVP/EFZ [n (%)] 21 (62) 18 (28) 13 (43)
TDF-3TC-NVP/EFZ [n (%)] 0 (0) 5 (8) 0 (0) 0.008
*Chi square test was used for categorical variables and Kruskal-Wallis test was used for the continuous variables.
∏All patients initiated antiretroviral therapy at CD4 200 cells/μl and below. The magnitude of CD4 increase from the baseline counts was grouped into 4
quartiles; ‘Suboptimal CD4 reconstitution’ includes patients that lie in the lowest quartile, ‘Optimal CD4 reconstitution’ includes a sample of patients that lie in
the two middle quartiles and ‘Super-optimal CD4 reconstitution’ includes patients that lie in the highest quartile of CD4 increase.
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multivariate analysis these parameters were not signifi-
cant predictors of suboptimal CD4 reconstitution (data
not shown).
Co-infections
All participants were tested for concurrent acute infec-
tions that are associated with immune activation. Of the
128 patients with sustained viral suppression, 7(6%)
were positive for hepatitis B surface antigen, only 13
(10%) had a C-reactive protein level above 6 mg/dl. No
intestinal parasitic infection was observed in all partici-
pants using both stool microscopy for ova and parasites
and modified ZN stain.
Discussion
Immune activation, as defined by expression of HLA-DR
and CD38 by T-cells typically normalizes several months
following successful initiation of ART [20]. However, we
describe high levels of immune activation in a cohort of
HIV infected Ugandan adults four years following ART;
a report that is consistent with several other studies
from the Western cohorts [21,22]. Contrary to previous
studies from the West [10], this study demonstrated
that suboptimal CD4 reconstitution is strongly asso-
ciated elevated T cell activation, regardless of initial clin-
ical parameters. Various immunosuppressive agents have
been investigated in the interest of “turning off” exces-
sive immune activation [23,24] as an intervention to
improve patients’ responses to ART. Therefore down-
regulation of immune activation is a potential strategy
to optimize immune recovery among ART-treated
patients with suboptimal CD4 reconstitution. Note-
worthy, the study participants were started on ART at
CD4 counts < 250 cells/μl. This is clearly severe
immune suppression considering the growing evidence
initiation of ART at higher CD4 counts yields better
clinical and immunological outcomes [25,26]. This study
adds evidence to the current evidence that early initia-
tion of ART not only increases CD4 counts and survival
[6,25-27], but also lowers the levels of T-cell activation
 
 
Figure 2 Flow cytometry analysis of CD38+HLADR+ CD8 T cells. The upper panel shows the gating strategy for co-expression of CD38 and
HLADR (immune activation) by CD8 T cells. The lower panel shows a ‘super responder’ with a typically low proportion of activated CD8 T cells
(left) and a ‘suboptimal responder’ with a typically high proportion of activated CD8 T cells.
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Figure 3 T-cell activation and magnitude of CD4 count increase among HIV-infected patients after 4 years of antiretroviral therapy and
sustained HIV-RNA viral suppression. Immune activation, was measured by co-expression of HLADR and CD38 (CD38+HLADR+). The percentages
of activated CD4 (CD438+HLADR+) and CD8 (CD8 CD38+ HLADR+) T-cells were plotted against CD4 count reconstitution. Immune activation of CD4
and CD8 T-cells was higher among patients with suboptimal CD4 reconstitution (patients that lie in the lowest quartile of CD4 increase) relative to the
super-optimal responders (patients that lie in the highest quartile of CD4 increase) P = 0.001. The boxes span the 25th and 75th percentile values, the
error bars span the 10th and 90th percentile values, and the dots represent individual observations above the 90th percentile values.
 
 
Figure 4 Flow cytometry analysis of PD1+ CD4 T cells for an individual with suboptimal CD4 reconstitution. The upper panel shows the
gating strategy for the PD1+ T cells that are marked for apoptosis. The lower panel shows the fluorescence minus one control (FMO) for PD1
(left) and a typically high proportion of PD1+ cells (right).
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Figure 5 T-cell exhaustion among HIV-infected patients after 4 years of antiretroviral therapy with sustained HIV-RNA viral
suppression. T-cell exhaustion was measured by expression of programmed cell death 1 (PD-1) by CD4 and CD8 cells (CD4 PD1+ and CD8 PD1
+). The percentages of CD4 PD1+ and CD8 PD1+ T-cells were plotted against CD4 count reconstitution. Exhaustion of CD4 and CD8 T-cells was
significantly higher among patients with suboptimal CD4 reconstitution (patients that lie within the lowest quartile of CD4 increase) relative to
optimal responders (patients that lie within the middle quartiles of CD4 increase and super-optimal responders (patients that lie within the
highest quartile of CD4 increase) P = 0.001. The boxes span the 25th and 75th percentile values, the error bars span the 10th and 90th percentile
values, and the dots represent individual observations above the 90th percentile values.
Table 2 T-cell immune activation, cell exhaustion and peripheral blood parameters among patients with and without
suboptimal CD4 reconstitution after 4 years of antiretroviral therapy
Parameters measured after 4 years of ART Suboptimal CD4
reconstitution
(Cases) N = 34
Super-Optimal CD4
reconstitution
(Controls) N = 30
P-value * Adjusted OR
(95% CI)
P-value
Immune activation
CD4 HLADR+ CD38+ [Median (IQR)] 7.9 (4.9-16.4) 2.8 (2.0-3.6) < 0.001 5.7 (1.4-23.0) 0.014
CD8 HLADR+ CD38+ [Median (IQR)] 22.5 (15.3-44.9) 10.3 96.3-15.1) < 0.001 0.8 (0.6-1.1) 0.107
Cell exhaustion
CD4 PD1+ [Median (IQR)] 34.3 (17.6-78.8) 7.3 (4.7-9.4) < 0.001 1.5 (1.1-2.1) 0.022
CD8 PD1+ [Median (IQR)] 30.6 (13.4-82.9) 7.9 (6.2-9.5) < 0.001 1.2 (0.9-1.5) 0.130
Peripheral blood parameters
Hemoglobin (mg/dl) [Median (IQR)] 13 (12-14) 14 (12-15) 0.293
MCV (fl) [Median (IQR)] 102 (96-112) 109 (98-112) 0.264
Total white blood cell count
[Median (IQR)]
3530 (3000-4050) 5050 (4240-5720) 0.003
Lymphocytes % [Median (IQR)] 37 (30-46) 45 (36-51) 0.278
Neutrophils % [Median (IQR)] 45 (40-59) 42 (38-50) 0.820
Eosinophils % [Median (IQR)] 4 (1-8) 2 (1-3) 0.012
Platelet count nx103 [Median (IQR)] 235 (205-284) 292 (214-318) 0.359
*Wilcoxon rank-sum test, ¥ Chi square, MCV, mean corpuscular volume.
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and possibly improves T-cell function recovery. There-
fore early targeted and aggressive intervention in the
population with suboptimal immune recovery may be
beneficial [28-30].
The high levels of T-cell immune-activation did not
correlate with the presence of co-infections including
tuberculosis, cryptococcal meningitis, Pneumocystis iiro-
veci pneumonia, toxoplasmosis, oro-esophageal candi-
diasis and malaria. This result is consistent with our
previous report that AIDS-related events were no more
among patients with and without suboptimal CD4
reconstitution [6]. Similarly, none of the patients was
found to have intestinal helminthiasis despite living in a
region where the infection is endemic. The authors
attribute this to the fact that this was a selected popula-
tion that receives comprehensive screening, treatment
and prevention of co-infections that includes among
others; cotrimoxazole prophylaxis, regular de-worming
and a safe water vessel; all of which reduce the risk of
the co-infections [31-34].
Expression of programmed cell death 1 (PD-1) was
significantly up-regulated on T-cells of suboptimal
responders relative to super-optimal responders. Signifi-
cant difference in T-cell immune activation and exhaus-
tion was observed despite undetectable viremia. This
implies that ongoing viral replication may not be the
driver of PD-1 expression as previously reported [35].
However, our results are in agreement with evidence
that increased apoptosis and intrinsic T-cell death play a
role in incomplete CD4 count recovery [7]. There is
need for further studies to determine other potential
drivers of both immune activation and PD-1 expression
among HIV-infected patients on successful ART. Simi-
larly, advances to regulate these immunological abnorm-
alities may modify CD4 count recovery among ART-
treated HIV-infected patients with suboptimal CD4
reconstitution.
Our study design did not permit determination of the
causation of immune dysregulation. Although majority
of available data suggests that immune activation is
most likely a cause of the damaged immune system
rather than a consequence [30], it is possible that lack
of CD4 recovery could be the cause and not a conse-
quence of the immune impairment [36]. We did not
compare levels of immune activation among patients
with and without viral suppression however there is
already evidence that ART decreases immune activation
levels over time [1,37].
Conclusion
T-cell activation and exhaustion persist among HIV-
infected patients despite long-term, sustained HIV-RNA
viral suppression. These immune abnormalities were
associated with suboptimal CD4 reconstitution and their
regulation may modify immune recovery among ART-
treated patients with suboptimal CD4 reconstitution
despite sustained viral suppression.
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